e18015 Background: CML is a malignant clonal disorder of the hematopoietic stem cells that results in an increased myeloid cells but also erythroid and platelets in the peripheral blood and marked myeloid hyperplasia in the bone marrow. The management of this condition in a rural community clinic is a challenge due to the complexity in the routine monitor of these patients with molecular studies. In addition, data from Hispanic population treated with imatinib in USA is limited. Methods: A total of 15 patient with CML followed in a private clinic form June 2001 to January 2012 were included in the analysis for the study. Results: The patients included 10 males and 5 females. Median age was 51 years. All patients received imatinib 400mg. There were 4 patients with initial WBC > 50,000/mm3. All patients were in chronic phase with less 1% of blasts, except for one that had 7%. Twelve patients had a low Harford score, 2 with moderate and 1 high risk. Conclusions: Our data suggest that imatinib is highly effective in this population of patients. The CCR at 6 months was 80% and the MMR at 12 months was 80% compared with the data from the IRIS (CCR at 6 months, 74.7%) and DASISON (MMR at 12 months, 28%) trials. This group of patients demonstrates high CHR, CCR and MMR in comparison of what is reported in the literature. The study also present a group of Hispanic patients were the information about imatinib response is limited. The possibly that certain ethnic group has a different pattern of response as compared with Caucasian is intriguing. Lastly, it is evident that adequate care could be offer event in rural community clinics. [Table: see text]
Rapid and Durable Symptom Palliation with QUAD shot Radiotherapy to Non-Osseous Metastatic/Recurrent Cancer in Elderly or Frail Patients in a Rural Community Clinic
